202 related articles for article (PubMed ID: 25635886)
41. Clinical Implications of Accurate Subtyping of Pituitary Adenomas: Perspectives from the Treating Physician.
Gomez-Hernandez K; Ezzat S; Asa SL; Mete Ö
Turk Patoloji Derg; 2015; 31 Suppl 1():4-17. PubMed ID: 26177314
[TBL] [Abstract][Full Text] [Related]
42. ACTH adenomas transforming their clinical expression: report of 5 cases.
Zoli M; Faustini-Fustini M; Mazzatenta D; Marucci G; De Carlo E; Bacci A; Pasquini E; Lanzino G; Frank G
Neurosurg Focus; 2015 Feb; 38(2):E15. PubMed ID: 25639317
[TBL] [Abstract][Full Text] [Related]
43. Delayed Craniospinal Metastasis of Aggressive Nonfunctioning Pituitary Adenomas as Pituitary Carcinomas.
Raghu ALB; Everson MC; Helal A; Kiyofuji S; Clarke MJ; Link MJ
J Neurol Surg B Skull Base; 2022 Jun; 83(Suppl 2):e253-e259. PubMed ID: 35832993
[No Abstract] [Full Text] [Related]
44. [Pathology and pathogenesis of pituitary corticotroph adenoma].
Trouillas J
Neurochirurgie; 2002 May; 48(2-3 Pt 2):149-62. PubMed ID: 12058122
[TBL] [Abstract][Full Text] [Related]
45. Therapeutic implications of accurate classification of pituitary adenomas.
Mete O; Asa SL
Semin Diagn Pathol; 2013 Aug; 30(3):158-64. PubMed ID: 24144285
[TBL] [Abstract][Full Text] [Related]
46. Pituitary tumors: prognostic indicators.
Saeger W
Endocrine; 2005 Oct; 28(1):57-66. PubMed ID: 16311411
[TBL] [Abstract][Full Text] [Related]
47. Complex endocrinopathies in MEN-1: diagnostic dilemmas in endocrine oncology.
Al Brahim NY; Rambaldini G; Ezzat S; Asa SL
Endocr Pathol; 2007; 18(1):37-41. PubMed ID: 17652799
[TBL] [Abstract][Full Text] [Related]
48. Treatment of Aggressive Pituitary Adenomas: A Case-Based Narrative Review.
Cooper O; Bonert V; Liu NA; Mamelak AN
Front Endocrinol (Lausanne); 2021; 12():725014. PubMed ID: 34867776
[TBL] [Abstract][Full Text] [Related]
49. [Relationship between invasive pituitary adenomas and cavernus sinus and cariod artery and surgical outcomes].
Ren ZY; Yang Y; Su CB; Wang RZ; Tao W; Ma WB; Li YN
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Feb; 27(1):13-7. PubMed ID: 15782485
[TBL] [Abstract][Full Text] [Related]
50. Cytokeratin CK20 is a sensitive marker for Crooke's cells and the early cytoskeletal changes associated with hypercortisolism within pituitary corticotrophs.
Eschbacher JM; Coons SW
Endocr Pathol; 2006; 17(4):365-76. PubMed ID: 17525485
[TBL] [Abstract][Full Text] [Related]
51. Refractory pituitary adenoma: a novel classification for pituitary tumors.
Dai C; Feng M; Liu X; Ma S; Sun B; Bao X; Yao Y; Deng K; Wang Y; Xing B; Lian W; Zhong D; Ma W; Wang R
Oncotarget; 2016 Dec; 7(50):83657-83668. PubMed ID: 27845901
[TBL] [Abstract][Full Text] [Related]
52. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium.
Daly AF; Rixhon M; Adam C; Dempegioti A; Tichomirowa MA; Beckers A
J Clin Endocrinol Metab; 2006 Dec; 91(12):4769-75. PubMed ID: 16968795
[TBL] [Abstract][Full Text] [Related]
53. Correlates of long-term hypocortisolism after transsphenoidal microsurgery for Cushing's disease.
Flitsch J; Lüdecke DK; Knappe UJ; Saeger W
Exp Clin Endocrinol Diabetes; 1999; 107(3):183-9. PubMed ID: 10376443
[TBL] [Abstract][Full Text] [Related]
54. Approach to the Treatment of a Patient with an Aggressive Pituitary Tumor.
Lin AL; Donoghue MTA; Wardlaw SL; Yang TJ; Bodei L; Tabar V; Geer EB
J Clin Endocrinol Metab; 2020 Dec; 105(12):3807-20. PubMed ID: 32930787
[TBL] [Abstract][Full Text] [Related]
55. Pituitary tumor transforming gene and insulin-like growth factor 1 receptor expression and immunohistochemical measurement of Ki-67 as potential prognostic markers of pituitary tumors aggressiveness.
Sánchez-Tejada L; Sánchez-Ortiga R; Moreno-Pérez O; Montañana CF; Niveiro M; Tritos NA; Alfonso AM
Endocrinol Nutr; 2013; 60(7):358-67. PubMed ID: 23416216
[TBL] [Abstract][Full Text] [Related]
56. Immunohistochemical study of crooke's hyaline change.
Uei Y; Kanzaki M; Ohta T
Endocr Pathol; 1991 Mar; 2(1):12-15. PubMed ID: 32357618
[TBL] [Abstract][Full Text] [Related]
57. Clinicopathological characteristics and therapeutic outcomes in thyrotropin-secreting pituitary adenomas: a single-center study of 90 cases.
Yamada S; Fukuhara N; Horiguchi K; Yamaguchi-Okada M; Nishioka H; Takeshita A; Takeuchi Y; Ito J; Inoshita N
J Neurosurg; 2014 Dec; 121(6):1462-73. PubMed ID: 25237847
[TBL] [Abstract][Full Text] [Related]
58. Aggressive Pituitary Adenomas and Carcinomas.
Ilie MD; Jouanneau E; Raverot G
Endocrinol Metab Clin North Am; 2020 Sep; 49(3):505-515. PubMed ID: 32741485
[TBL] [Abstract][Full Text] [Related]
59. [Gonadotroph pituitary adenomas].
Chanson P
Ann Endocrinol (Paris); 2000 Sep; 61(3):258-68. PubMed ID: 10970952
[TBL] [Abstract][Full Text] [Related]
60. [Effects of irradiation therapy and inhibiting drugs on the pituitary and its adenomas].
Saeger W
Pathologe; 2006 Feb; 27(1):57-60. PubMed ID: 16362259
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
